{"id":"vaccinate-with-dtap","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Injection site pain, redness, or swelling"},{"rate":"10-15","effect":"Fever"},{"rate":"10-20","effect":"Fussiness or irritability"},{"rate":"5-10","effect":"Drowsiness"},{"rate":"5-10","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DTaP is a combination vaccine containing inactivated diphtheria and tetanus toxoids and acellular pertussis antigen. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize the corresponding pathogens if encountered naturally. This provides protection against diphtheria, tetanus, and pertussis (whooping cough).","oneSentence":"DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:35.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria in infants and children"},{"name":"Prevention of tetanus in infants and children"},{"name":"Prevention of pertussis (whooping cough) in infants and children"}]},"trialDetails":[{"nctId":"NCT06793826","phase":"","title":"Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-17","conditions":"Hepatitis B, Haemophilus Influenzae Type b Immunisation","enrollment":713},{"nctId":"NCT07112144","phase":"PHASE3","title":"Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial","status":"RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-06-13","conditions":"Prevent Whooping Cough, Prevent Diphtheria, Prevent Tetanus","enrollment":1650},{"nctId":"NCT05870618","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT05870631","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT02610348","phase":"NA","title":"Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-11","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT03142139","phase":"","title":"Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"1997-01-01","conditions":"Atopic Dermatitis","enrollment":1027559}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1065,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"vaccinate with DTaP","genericName":"vaccinate with DTaP","companyName":"Zhejiang Provincial Center for Disease Control and Prevention","companyId":"zhejiang-provincial-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}